MedTrace Logo

Persistence of Bactericidal Antibodies in Adolescents and Adults Who Had Received a Single Dose of Menactra® Vaccine

NCT00862277 · Status: COMPLETED · Type: OBSERVATIONAL · Enrollment: 763

Last updated 2016-04-14

Study results available
· View outcomes & findings →

Summary

To evaluate the persistence of bactericidal antibodies in adolescents and adults who received one dose of Menactra® vaccine approximately four to eight years earlier

Conditions

Interventions

BIOLOGICAL

Menactra®

0.5 mL, Intramuscular (from a previous study)

BIOLOGICAL

Menomune®

0.5 mL, Intramuscular (from a previous study)

Sponsors & Collaborators

  • Sanofi Pasteur, a Sanofi Company

    lead INDUSTRY

Principal Investigators

  • Medical Director · Sanofi Pasteur Inc.

Eligibility

Min Age
14 Years
Max Age
27 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2008-12-31
Primary Completion
2009-03-31
Completion
2009-12-31

Countries

  • United States

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00862277 on ClinicalTrials.gov